Clinical Study on Irbesartan and Aspirin Combined with Tetramethylpyrazine in the Treatment of Early Diabetic Nephropathy
- VernacularTitle:厄贝沙坦、阿司匹林、川芎嗪联合治疗早期糖尿病肾病的临床观察
- Author:
Zhengfang LI
;
Yang TAN
- Publication Type:Journal Article
- Keywords:
Irbesartan;
Enteric-coated aspirin;
Tetramethylpyrazine;
Diabetic nephropathy
- From:
China Pharmacy
2001;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To explore the clinical efficacy of irbesartan, enteric-coated aspirin combined with tetramethylpyrazine in the treatment of diabetic nephropathy. METHODS: 75 patients with diabetic nephropathy were randomly divided into treatment group(n=40) and control group(n=35). Both groups were administered with 150 mg irbesartan(p.o.) and 100 mg enteric-coated aspirin (p.o.) once a day. Treatment group were additionally treated with 0.9% normal saline containing 200 mg tetramethylpyrazine once a day (i.v.gtt). During 28 days of treatment, treatment group was compared with control group in respect of 24-h urine protein, blood lipids, blood rheology. RESULTS: After treatment, hemorheological indexes (?b, EAI), renal function indexes(Scr、BUN、24-h urine protein) , Serum lipids(TG, TC) were decreased significantly(P
